Cytosorbents Stock Forecast, Price & News

-0.27 (-3.40 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume390,160 shs
Average Volume293,371 shs
Market Capitalization$332.26 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

Cytosorbents logo

About Cytosorbents

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.69 out of 5 stars

Medical Sector

339th out of 2,097 stocks

Surgical & Medical Instruments Industry

33rd out of 174 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

Is Cytosorbents a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cytosorbents stock.
View analyst ratings for Cytosorbents
or view top-rated stocks.

What stocks does MarketBeat like better than Cytosorbents?

Wall Street analysts have given Cytosorbents a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cytosorbents wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cytosorbents' next earnings date?

Cytosorbents is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Cytosorbents

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) announced its quarterly earnings data on Tuesday, May, 4th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.07. The medical research company earned $10.60 million during the quarter, compared to the consensus estimate of $11.40 million. Cytosorbents had a negative trailing twelve-month return on equity of 13.11% and a negative net margin of 19.94%.
View Cytosorbents' earnings history

How has Cytosorbents' stock price been impacted by COVID-19 (Coronavirus)?

Cytosorbents' stock was trading at $4.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CTSO stock has increased by 60.8% and is now trading at $7.67.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CTSO?

3 brokerages have issued 12-month price targets for Cytosorbents' shares. Their forecasts range from $15.00 to $17.00. On average, they anticipate Cytosorbents' share price to reach $15.67 in the next twelve months. This suggests a possible upside of 104.3% from the stock's current price.
View analysts' price targets for Cytosorbents
or view top-rated stocks among Wall Street analysts.

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the following people:
  • Dr. Phillip P. Chan, CEO & Director (Age 51, Pay $728.08k)
  • Mr. Vincent J. Capponi M.S., MS, Pres & COO (Age 63, Pay $597.21k)
  • Ms. Kathleen P. Bloch CPA, M.B.A., MBA, CPA, CFO & Sec. (Age 66, Pay $487.85k)
  • Dr. Efthymios N. Deliargyris M.D., FACC, FESC, FSCAI, Chief Medical Officer (Age 53, Pay $490.11k)
  • Dr. Christian Steiner M.D., Exec. VP of Sales & Marketing
  • Mr. Christopher Cramer, VP of Bus. Devel.
  • Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 82)

What is Phillip Chan's approval rating as Cytosorbents' CEO?

2 employees have rated Cytosorbents CEO Phillip Chan on Phillip Chan has an approval rating of 26% among Cytosorbents' employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cytosorbents' key competitors?

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.53%), Redmile Group LLC (4.91%), Skylands Capital LLC (3.64%), Neuberger Berman Group LLC (1.99%), Sargent Investment Group LLC (1.81%) and Geode Capital Management LLC (1.52%). Company insiders that own Cytosorbents stock include Kathleen P Bloch, Phillip P Chan and Vincent Capponi.
View institutional ownership trends for Cytosorbents

Which institutional investors are selling Cytosorbents stock?

CTSO stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Goldman Sachs Group Inc., AWM Investment Company Inc., Neuberger Berman Group LLC, Bank of New York Mellon Corp, Northern Trust Corp, Cubist Systematic Strategies LLC, and New York State Common Retirement Fund.
View insider buying and selling activity for Cytosorbents
or view top insider-selling stocks.

Which institutional investors are buying Cytosorbents stock?

CTSO stock was acquired by a variety of institutional investors in the last quarter, including Avenir Corp, Wealth Advisory Solutions LLC, CM Management LLC, Sargent Investment Group LLC, Renaissance Technologies LLC, Geode Capital Management LLC, Redmile Group LLC, and BlackRock Inc.. Company insiders that have bought Cytosorbents stock in the last two years include Kathleen P Bloch, and Phillip P Chan.
View insider buying and selling activity for Cytosorbents
or or view top insider-buying stocks.

How do I buy shares of Cytosorbents?

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $7.67.

How much money does Cytosorbents make?

Cytosorbents has a market capitalization of $332.26 million and generates $41.01 million in revenue each year. The medical research company earns $-7,840,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

How many employees does Cytosorbents have?

Cytosorbents employs 195 workers across the globe.

What is Cytosorbents' official website?

The official website for Cytosorbents is

Where are Cytosorbents' headquarters?

Cytosorbents is headquartered at 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]

This page was last updated on 6/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.